Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor

Clinical data and research indicate that bispecific antibodies have significant immunotherapeutic potential and may soon become available to treat solid tumors. Exploring the potential of bispecific antibodies as treatment options for patients with small cell lung, prostate, gastrointestinal, and other cancers,

Building upon its important work in the bispecific antibodies space, the Association of Cancer Care Centers (ACCC) has developed an educational program to prepare care teams for the delivery of these treatments in community and rural cancer programs when they become available. This program explores the latest findings in solid tumor applications and best practices for the use of bispecific antibodies in cancer care.

For more information about this project, please contact the ACCC Provider Education Department.

This project is sponsored by Amgen; however, Amgen did not exert any editorial control on the content.